Y Intercept (Hong Kong) LTD Abb Vie Inc. Transaction History

Y Intercept (Hong Kong) LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $1.94 Million - $2.26 Million	12,505 New	12,505 $2.14 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $955,356 - $1.08 Million	6,943 New	6,943 $1.08 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $4.48 Million - $5.57 Million	33,789 New	33,789 $4.55 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $1.49 Million - $1.79 Million	-10,765 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$134.21 - $153.93 $1.44 Million - $1.66 Million	10,765 New	10,765 $1.44 Million
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $408,895 - $464,157	-3,843 Closed	0 $0
Q2 2021 Aug 26, 2021	BUY	$105.21 - $117.21 $404,322 - $450,438	3,843 New	3,843 $433,000
Q2 2021 Aug 12, 2021	SELL	$105.21 - $117.21 $269,232 - $299,940	-2,559 Closed	0 $433,000
Q1 2021 May 12, 2021	BUY	$102.3 - $112.62 $261,785 - $288,194	2,559 New	2,559 $273,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.